The evidence has moved beyond one pilot
A 2025 phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment and followed them for nine weeks. That was an early controlled test, not a definitive answer about routine addiction care. By 2026, additional randomized studies had been published. Reading only the first headline now leaves out evidence from other populations and formulations, including results that differ by the outcome measured.[1]
A longer trial included behavioral treatment
A 2026 study enrolled 108 people with alcohol use disorder and obesity for 26 weeks. Both groups received cognitive behavioral therapy; one received injectable semaglutide and the other placebo. The reported difference in reduction of heavy-drinking days favored semaglutide by 13.7 percentage points. This result concerns treatment added to that care setting in that population. It should not be presented as evidence that a prescription alone replaces behavioral treatment.[2]
The oral study had a mixed pattern
An eight-week oral semaglutide study randomized 50 treatment-seeking participants. It did not find a significant benefit for its primary laboratory craving outcome or drinks per day, while some secondary measures, including heavy-drinking days, favored treatment. That distinction belongs beside the positive findings. Selecting only a favorable secondary result would hide the main question the study was designed to answer.[3]
Different endpoints are not competing versions of one number
Laboratory consumption, craving, heavy-drinking days and total drinks measure different aspects of alcohol use. A treatment could change one more clearly than another. Likewise, treatment-seeking participants may differ from people enrolled without seeking care. These differences help explain why results should be compared carefully instead of averaged into a single claim that the medicine reduces drinking by a fixed percentage. Related reading: how to read GLP-1 research. For a related question, see how appetite outcomes are measured.
What these trials do not establish
These findings do not establish that every GLP-1 formulation has the same effect or that an online weight-loss program provides addiction treatment. They also do not tell an individual which treatment is appropriate. The evidence supports further clinical research, while the care decision belongs with professionals able to assess alcohol use, other conditions and treatment needs. A commercial product offer is a separate question from a trial result.
Do not use a weight-loss subscription as a detox plan
Someone concerned about alcohol use should seek an appropriate clinical assessment rather than attempt to reproduce a research protocol. Trials include eligibility screening and supervision that a general medication comparison does not provide. Discuss the concern directly with a healthcare professional and do not make abrupt changes to established care based on this article. The purpose here is to explain evidence, not to supply an alcohol-withdrawal or medication regimen.
What would strengthen the evidence next
Larger studies, longer follow-up and clear comparisons with established care would help clarify who benefits and which outcomes improve. Retention, adverse events and outcomes after treatment ends are also important. Check whether a future publication reports the prespecified primary result as well as secondary findings. A balanced account should preserve unfavorable or uncertain results, not just the outcomes most suitable for a headline.
Keep product evidence separate from marketing
A study of one formulation cannot validate a compounded preparation or a claim made by a clinic selling a different product. Ask which exact study supports a proposed medical claim and whether the setting matches the claim being made. The same discipline used to compare branded and compounded weight-management products is useful here, but no provider recommendation follows from these early addiction studies. Related reading: product-status distinctions.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- 2025 injectable semaglutide randomized trial
- 2026 semaglutide trial in alcohol use disorder and obesity
- 2026 oral semaglutide randomized trial
Prices and terms can change. Confirm your specific offer directly with the provider.